StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck dificid (fidaxomicin — C. difficile infection) — Worldwide sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

QuarterlyAnnual
Latest, FY2025
247
Period ended Dec 31, 2025
Change on a year earlier
-27.4%
340 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDificid (fidaxomicin — C. difficile infection) — Worldwide sales ($M) ($M)Year on yearSource
FY2025Dec 31, 2025247-27.4%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
FY2024Dec 31, 2024340+12.6%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2023Dec 31, 2023302+14.8%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
FY2022Dec 31, 2022263+50.3%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
FY2021Dec 31, 2021175+59.1%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
FY2020Dec 31, 2020110–Form 10-K (filed 2023-02-24) ↗

Breakdown

What makes up dificid (fidaxomicin — c. difficile infection) — worldwide sales ($m)

Cite this data

StockData. (2026). Merck Dificid (fidaxomicin — C. difficile infection) — Worldwide sales ($M) ($M), annual FY2020–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_dificid

See every metric in the Merck KPI table. Data updated Oct 26, 2026.